Shen Y - Search Results

1

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.

Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. Lim B, et al. Among authors: shen y. Br J Cancer. 2019 Jun;120(12):1105-1112. doi: 10.1038/s41416-019-0473-y. Epub 2019 May 17. Br J Cancer. 2019. PMID: 31097774 Free PMC article. Clinical Trial.

2

High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.

Cortes J, Estey E, O'Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, Kantarjian H. Cortes J, et al. Among authors: shen y. Cancer. 2001 Jul 1;92(1):7-14. doi: 10.1002/1097-0142(20010701)92:1<7::aid-cncr1285>3.0.co;2-d. Cancer. 2001. PMID: 11443603 Clinical Trial.

3

High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.

Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ, Cortes J, Thomas DA, Faderl S, Despa S, Estey EH. Beran M, et al. Among authors: shen y. Cancer. 2001 Oct 15;92(8):1999-2015. doi: 10.1002/1097-0142(20011015)92:8<1999::aid-cncr1538>3.0.co;2-b. Cancer. 2001. PMID: 11596013

4

Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.

Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, Kontoyiannis D, Koller C, Munsell M, Beran M, Kantarjian H. Mattiuzzi GN, et al. Among authors: shen y. Cancer. 2003 Jan 15;97(2):450-6. doi: 10.1002/cncr.11094. Cancer. 2003. PMID: 12518369 Free article. Clinical Trial.

5

Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors.

Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ. Davis DW, et al. Among authors: shen y. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):33-42. doi: 10.1158/1078-0432.ccr-0736-3. Clin Cancer Res. 2004. PMID: 14734449

6

The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.

Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ. Kamat AM, et al. Among authors: shen y. Mol Cancer Ther. 2004 Mar;3(3):279-90. Mol Cancer Ther. 2004. PMID: 15026548

7

Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.

Hu Q, Dey AL, Yang Y, Shen Y, Jilani IB, Estey EH, Kantarjian HM, Giles FJ, Albitar M. Hu Q, et al. Among authors: shen y. Cancer. 2004 May 1;100(9):1884-91. doi: 10.1002/cncr.20187. Cancer. 2004. PMID: 15112269 Free article.

8

A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate?

Sánchez-Ortiz RF, Madsen LT, Bermejo CE, Wen S, Shen Y, Swanson DA, Wood CG. Sánchez-Ortiz RF, et al. Among authors: shen y. Cancer. 2004 Nov 15;101(10):2195-201. doi: 10.1002/cncr.20638. Cancer. 2004. PMID: 15470708 Free article.

9

Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.

Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Davis DW, et al. Among authors: shen y. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):678-89. Clin Cancer Res. 2005. PMID: 15701856

10

Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach.

Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF. Berry DA, et al. Among authors: shen y. J Natl Cancer Inst Monogr. 2006;(36):30-6. doi: 10.1093/jncimonographs/lgj006. J Natl Cancer Inst Monogr. 2006. PMID: 17032892

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26,357 results

Search Page